Safety and Immunogenicity of MSB11455 in Healthy Participants

NCT03251339 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

336

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: MSB11455
DRUG: US-Neulasta

Sponsor

Fresenius Kabi SwissBioSim GmbH